PH12021552094A1 - Method for preparing influenza ha split vaccine - Google Patents

Method for preparing influenza ha split vaccine

Info

Publication number
PH12021552094A1
PH12021552094A1 PH1/2021/552094A PH12021552094A PH12021552094A1 PH 12021552094 A1 PH12021552094 A1 PH 12021552094A1 PH 12021552094 A PH12021552094 A PH 12021552094A PH 12021552094 A1 PH12021552094 A1 PH 12021552094A1
Authority
PH
Philippines
Prior art keywords
influenza
split vaccine
stem region
preparing influenza
preparing
Prior art date
Application number
PH1/2021/552094A
Other languages
English (en)
Inventor
Yu Adachi
Manabu Ato
Yoshimasa Takahashi
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Sumitomo Pharma Co Ltd filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of PH12021552094A1 publication Critical patent/PH12021552094A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PH1/2021/552094A 2019-03-04 2020-03-03 Method for preparing influenza ha split vaccine PH12021552094A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
PH12021552094A1 true PH12021552094A1 (en) 2022-05-30

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552094A PH12021552094A1 (en) 2019-03-04 2020-03-03 Method for preparing influenza ha split vaccine

Country Status (14)

Country Link
US (1) US20220152191A1 (en])
EP (1) EP3936147A4 (en])
JP (1) JP7545955B2 (en])
KR (1) KR20210135261A (en])
CN (1) CN114096273A (en])
AU (1) AU2020233456A1 (en])
BR (1) BR112021017310A8 (en])
CA (1) CA3132578A1 (en])
EA (1) EA202192398A1 (en])
IL (1) IL285984A (en])
MX (1) MX2021010685A (en])
PH (1) PH12021552094A1 (en])
SG (1) SG11202109566XA (en])
WO (1) WO2020179797A1 (en])

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019311965A1 (en) 2018-07-23 2021-02-25 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
TW202506714A (zh) * 2023-04-26 2025-02-16 國立感染症研究所長代表之日本國 抗流感抗體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CN102223895B (zh) * 2008-11-25 2014-11-05 巴克斯特保健股份有限公司 生产pH稳定的包膜病毒的方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
WO2017056494A1 (en) * 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
EP3603619B1 (en) * 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
AU2019311965A1 (en) * 2018-07-23 2021-02-25 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN113194986A (zh) * 2018-12-26 2021-07-30 大日本住友制药株式会社 包括疫苗佐剂的制剂
CA3131551A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Also Published As

Publication number Publication date
BR112021017310A2 (en]) 2021-11-16
KR20210135261A (ko) 2021-11-12
BR112021017310A8 (pt) 2022-12-06
SG11202109566XA (en) 2021-10-28
WO2020179797A1 (ja) 2020-09-10
MX2021010685A (es) 2021-12-10
EP3936147A1 (en) 2022-01-12
AU2020233456A1 (en) 2021-10-07
EA202192398A1 (ru) 2021-11-23
IL285984A (en) 2021-10-31
JP7545955B2 (ja) 2024-09-05
JPWO2020179797A1 (en]) 2020-09-10
US20220152191A1 (en) 2022-05-19
CA3132578A1 (en) 2020-09-10
EP3936147A4 (en) 2022-09-28
CN114096273A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
PH12020500414A1 (en) Method for producing influenza ha split vaccine
PH12021552094A1 (en) Method for preparing influenza ha split vaccine
EA201691993A1 (ru) Вакцина к вирусу эпидемической диареи свиней
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
NZ729150A (en) Antiretroviral agents
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
WO2016207853A3 (en) Antigenically matched influenza vaccines
PH12016500473A1 (en) Pcv2b divergent vaccine composition and methods of use
BR112018010679A2 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
MX394775B (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
PH12014500369A1 (en) Influenza h5 vaccines
PH12017501795B1 (en) Pestivirus vaccines for congenital tremors
PH12020500042A1 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
JP2019043937A5 (en])
MX2022006005A (es) Metodo para producir virus de la influenza reagrupados.
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2017014146A (es) Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7.
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
WO2018029383A8 (de) Infektiöse bronchitis (ib)-virus varianten und diesbezügliche zusammensetzungen, verwendungen und verfahren
MX2022004065A (es) Preparacion de 2-cloro-1-(2-clorotiazol-5-il)etanona.
EA202190351A1 (ru) Композиция, входящая в состав вакцины против гриппа
PH12017502378A1 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2020006327A (es) Deteccion de vacunas vivas modificadas contra el virus de la gripe porcina.
UA92445U (ru) Способ коррекции иммунологической реактивности у детей, которые перенесли болезни инфекционного и неинфекционного генеза, предварительно привитых против кори и столбняка